Clinical trial
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
NCT00453167 · National Cancer Center, Korea, Other · Completed
Key facts
| NCT number | NCT00453167 |
|---|---|
| Title | Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer |
| Official title | A Phase II Study of Weekly Paclitaxel and Gemcitabine as Second-line Therapy in Patients With Metastatic or Recurrence Small Cell Lung Cancer |
| Lead sponsor | National Cancer Center, Korea, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Paclitaxel, Gemcitabine |
| Enrollment | 35 |
| Start date | Dec 1, 2005 |
| Primary completion | Dec 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | Mar 28, 2007 |
| Last update posted | Jul 12, 2010 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: